Remestemcel-L-rknd (Ryoncil): the first approved cellular therapy for steroid-refractory acute GVHD Available to Purchase

Until recently, the JAK1/2 inhibitor, ruxolitinib (Jakafi), was the only therapy for steroid-refractory acute graft-versus-host disease (SR-aGVHD) approved by the U.S. Food and Drug Administration (FDA) for use in patients older than 12 years. Now the FDA has approved a potent mesenchymal stromal cell product (MSC), remestemcel-L-rknd (Ryoncil), for children 18 and younger, showing 70% response rates and nearly 70% six-month survival. In this Spotlight, we highlight this important advance in the field.